A pediatrics journal has retracted a 2016 article purporting to be the first randomized controlled trial on the effects of vitamin D supplements on autism over concerns about the reliability of the findings.
The paper, “Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder,” appeared in the Journal of Child Psychology and Psychiatry and has been cited 27 times, according to Clarivate Analytics’ Web of Science, earning it a “highly cited paper” designation compared to its counterparts of a similar age.
The authors came from Egypt, Saudi Arabia, China, Chile, the UK and Norway. According to the abstract, the researchers looked at the effects of vitamin D supplements on 109 boys and girls with autism:
Food Science & Nutrition has retracted a 2018 article by a group of researchers in China and Pakistan for plagiarism. The article was titled “Experimentally investigated the asparagus (Asparagus officinalis L.) drying with flat-plate collector under the natural convection indirect solar dryer.”
The maker of a leading over-the-counter antacid has withdrawn its application for approval of the drug in China because a clinical trial of the product in that country was marred by “major protocol deviations.”
Researchers for the company, Reckitt Benckiser, maker of Gaviscon, had published a report on the study in 2015 in the journal Alimentary Pharmacology & Therapeutics. But the journal has now retracted the article, “Randomised clinical trial: The clinical efficacy and safety of an alginate‐antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China,” at the behest of the drug maker.
A group of Australian researchers who studied the cat’s meow as a model for urinary incontinence and other motor-neural issues in people have lost a 2015 paper in the wake of a misconduct investigation.
The target of the inquiry was Hari Subramanian, a former senior research fellow at the Queensland Brain Institute, part of the University of Queensland (UQ). Subramanian was leading studies of incontinence in the elderly, for which he sometimes used nerve stimulators on live rodents and cats. As The Australian reported last September, animal rights activists have objected to his research methods — which sometimes involved sticking probes into the brains of living animals.
Recently, the school launched an investigation — prompted by an unknown complainant — into the integrity of Subramanian’s data in two articles, including one, now retracted, that appeared in the Journal of Comparative Neurology.
The case is controversial, to say the least, replete with allegations of unfair attacks. Subramanian’s lawyer told us the journal may be reviewing its decision to retract the paper. (We couldn’t confirm that with the editor.)
A leading orthodontics journal has retracted 12 papers after determining that they contained either reused images, questionable data or both. Several of the articles involved experiments conducted in dogs — and one person familiar with the case told us that the duplication was an attempt to avoid sacrificing more animals than necessary for the research.
Although the list of authors on the articles varies, the common denominator is Jose Luis Calvo-Guirado, of the UCAM Universidad Católica San Antonio de Murcia, in Spain. Calvo-Guirado’s title at the institution is director de la Cátedra Internacional de Investigación en Odontología, which Google translates as director of the International Research Chair in Dentistry. Calvo-Guirado also holds (or has held) a research professorship at SUNY Stony Brook in the Department of Prosthodontics and Digital Medicine, according to his CV.
Calvo-Guirado’s name is on at least 187 entries in PubMed. Of those, 40 appeared in Clinical Oral Implants Research, a Wiley title on whose editorial board the researcher served, according to his CV.
A researcher has retracted two 2014 papers, after discovering they had not gone through the proper approval process before being submitted.
The papers were part of a collaboration funded by the U.S. National Institutes of Health, which focused on solving protein structures. Adam Godzik, the senior author, told Retraction Watch that all papers had to be approved by a special committee before being submitted to a journal. Given the scale of the collaboration, the committee for the Joint Center for Structural Genomics (JCSG) would assess whether researchers who had made a previous contribution to the work should be added as authors.
A pharmacy journal has retracted a 2017 cancer paper after determining that the lead author forged her co-author’s signature.
Alain Li Wan Po, editor-in-chief of the Journal of Clinical Pharmacy and Therapeutics, told Retraction Watch that, after discovering the forgery,the journal lost confidence in “the integrity of the whole report,” and decided to retract it:
Our judgment was that if an author is willing to forge a signature, we cannot be sure of the integrity of the whole report and decided on the retraction.
According to Po, the paper’s lead author, Yan Wang, objected to the retraction because “she maintained that the data were accurate.” So the editors retracted the paper without her approval — but with the agreement of the author Jatinder Lamba, whose name was forged.
How did the journal discover the forged signature?